Obtenga las últimas noticias sobre las acciones de Shattuck Labs con actualizaciones sobre las tendencias del mercado, las finanzas y el análisis de Benzinga. Manténgase informado sobre el rendimiento de STTK

Últimas noticias sobre

SHATTUCK LABS INC

Shattuck Labs

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Levi Strauss

News

Pre-Market Outlook

Markets

Movers

AREB

BJDX

CHSN

CVRX

GLXG

GRFX

IPDN

IVDA

KNOP

KPTI

LEVI

PRSU

SOBR

STTK

SVRE

Levi sorprende al mercado con ganancias trimestrales mejores de lo esperado y una perspectiva 2025 que mantiene sin cambios.

Acciones de Levi Strauss suben un 10%; Aquí están 20 acciones que se mueven en el premercado de EE. UU.

Shattuck Labs Inc

Health Care

Press Releases

Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

Earnings

Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference

Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights

Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism

Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million

Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease

Financing

Management

Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors

Shattuck Labs Announces Participation in Upcoming Wedbush Securities Key Opinion Leader (KOL) and Company Panel

IRON

Adagene Inc. - ADS, each representing 1.25 ordinary shares

Adagene

Adverum Biotechnologies, Inc. - Common Stock

Adverum Biotechnologies

ALX Oncology Holdings Inc. - Common Stock

ALX Oncology Holdings

Alterity Therapeutics Limited - American Depositary Shares

Alterity Therapeutics

aTyr Pharma

Burning Rock Biotech Limited - American Depositary Shares

Burning Rock Biotech

BeyondSpring

Cibus

Clene

Connect Biopharma Holdings Limited - Ordinary Shares

Connect Biopharma Hldgs

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

EXoZymes

Fortress Biotech

InflaRx

Immix Biopharma

Immunic

Kalaris Therapeutics, Inc. - Common Stock

Kalaris Therapeutics

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

OKYO Pharma

PMV Pharma

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Pelthos Therapeutics

Quince Therapeutics

Sutro Biopharma

Unicycive Therapeutics, Inc. - Common Stock

Unicycive Therapeutics

Wedbush

Leerink Partners

Citigroup

Comments

Shattuck Labs Noticias bursátiles

Noticias

Últimas noticias sobre

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL